Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Cash & Equivalents (2016 - 2026)

Rockwell Medical filings provide 16 years of Cash & Equivalents readings, the most recent being $10.7 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 31.61% to $10.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.7 million, a 31.61% decrease, with the full-year FY2025 number at $10.7 million, down 31.61% from a year prior.
  • Cash & Equivalents hit $10.7 million in Q4 2025 for Rockwell Medical, down from $13.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $35.7 million in Q1 2021 to a low of $6.6 million in Q1 2024.
  • Median Cash & Equivalents over the past 5 years was $12.1 million (2024), compared with a mean of $15.0 million.
  • Biggest five-year swings in Cash & Equivalents: plummeted 72.72% in 2021 and later soared 74.35% in 2024.
  • Rockwell Medical's Cash & Equivalents stood at $13.3 million in 2021, then decreased by 23.93% to $10.1 million in 2022, then dropped by 11.08% to $9.0 million in 2023, then surged by 74.35% to $15.7 million in 2024, then tumbled by 31.61% to $10.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $10.7 million (Q4 2025), $13.6 million (Q3 2025), and $12.5 million (Q2 2025) per Business Quant data.